Global RNA Vaccines Market Growth 2025-2031
The global RNA Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of RNA has greatly favored the development of in vivo transfection strategies.
RNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of RNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
United States market for RNA Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for RNA Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for RNA Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key RNA Vaccines players cover Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “RNA Vaccines Industry Forecast” looks at past sales and reviews total world RNA Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected RNA Vaccines sales for 2025 through 2031. With RNA Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Vaccines industry.
This Insight Report provides a comprehensive analysis of the global RNA Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global RNA Vaccines market?
What factors are driving RNA Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do RNA Vaccines market opportunities vary by end market size?
How does RNA Vaccines break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes RNA especially attractive for vaccines and gene editing. RNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of RNA has greatly favored the development of in vivo transfection strategies.
RNA Vaccines & Therapeutics is in the development stage and there is no use in the market. The fastest research is Clinical phrase II, such as AGS-004 of Argos Therapeutics, SB-FIX, SB-318, SB-913 of Sangamo Therapeutics. The major application of RNA Vaccines & Therapeutics is for infectious disease, cancer and others. And infectious disease and cancer are the major applications.
United States market for RNA Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for RNA Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for RNA Vaccines is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key RNA Vaccines players cover Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “RNA Vaccines Industry Forecast” looks at past sales and reviews total world RNA Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected RNA Vaccines sales for 2025 through 2031. With RNA Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Vaccines industry.
This Insight Report provides a comprehensive analysis of the global RNA Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Individualized Cancer Treatment MRNA Vaccine
- Infectious Disease Treatment MRNA Vaccine
- Infection Prevention MRNA Vaccine
- Infectious Disease
- Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
What is the 10-year outlook for the global RNA Vaccines market?
What factors are driving RNA Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do RNA Vaccines market opportunities vary by end market size?
How does RNA Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Vaccines Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for RNA Vaccines by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for RNA Vaccines by Country/Region, 2020, 2024 & 2031
2.2 RNA Vaccines Segment by Type
2.2.1 Individualized Cancer Treatment MRNA Vaccine
2.2.2 Infectious Disease Treatment MRNA Vaccine
2.2.3 Infection Prevention MRNA Vaccine
2.3 RNA Vaccines Sales by Type
2.3.1 Global RNA Vaccines Sales Market Share by Type (2020-2025)
2.3.2 Global RNA Vaccines Revenue and Market Share by Type (2020-2025)
2.3.3 Global RNA Vaccines Sale Price by Type (2020-2025)
2.4 RNA Vaccines Segment by Application
2.4.1 Infectious Disease
2.4.2 Cancer
2.4.3 Other
2.5 RNA Vaccines Sales by Application
2.5.1 Global RNA Vaccines Sale Market Share by Application (2020-2025)
2.5.2 Global RNA Vaccines Revenue and Market Share by Application (2020-2025)
2.5.3 Global RNA Vaccines Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global RNA Vaccines Breakdown Data by Company
3.1.1 Global RNA Vaccines Annual Sales by Company (2020-2025)
3.1.2 Global RNA Vaccines Sales Market Share by Company (2020-2025)
3.2 Global RNA Vaccines Annual Revenue by Company (2020-2025)
3.2.1 Global RNA Vaccines Revenue by Company (2020-2025)
3.2.2 Global RNA Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global RNA Vaccines Sale Price by Company
3.4 Key Manufacturers RNA Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Vaccines Product Location Distribution
3.4.2 Players RNA Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RNA VACCINES BY GEOGRAPHIC REGION
4.1 World Historic RNA Vaccines Market Size by Geographic Region (2020-2025)
4.1.1 Global RNA Vaccines Annual Sales by Geographic Region (2020-2025)
4.1.2 Global RNA Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic RNA Vaccines Market Size by Country/Region (2020-2025)
4.2.1 Global RNA Vaccines Annual Sales by Country/Region (2020-2025)
4.2.2 Global RNA Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas RNA Vaccines Sales Growth
4.4 APAC RNA Vaccines Sales Growth
4.5 Europe RNA Vaccines Sales Growth
4.6 Middle East & Africa RNA Vaccines Sales Growth
5 AMERICAS
5.1 Americas RNA Vaccines Sales by Country
5.1.1 Americas RNA Vaccines Sales by Country (2020-2025)
5.1.2 Americas RNA Vaccines Revenue by Country (2020-2025)
5.2 Americas RNA Vaccines Sales by Type (2020-2025)
5.3 Americas RNA Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Vaccines Sales by Region
6.1.1 APAC RNA Vaccines Sales by Region (2020-2025)
6.1.2 APAC RNA Vaccines Revenue by Region (2020-2025)
6.2 APAC RNA Vaccines Sales by Type (2020-2025)
6.3 APAC RNA Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe RNA Vaccines by Country
7.1.1 Europe RNA Vaccines Sales by Country (2020-2025)
7.1.2 Europe RNA Vaccines Revenue by Country (2020-2025)
7.2 Europe RNA Vaccines Sales by Type (2020-2025)
7.3 Europe RNA Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Vaccines by Country
8.1.1 Middle East & Africa RNA Vaccines Sales by Country (2020-2025)
8.1.2 Middle East & Africa RNA Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa RNA Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa RNA Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Vaccines
10.3 Manufacturing Process Analysis of RNA Vaccines
10.4 Industry Chain Structure of RNA Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Vaccines Distributors
11.3 RNA Vaccines Customer
12 WORLD FORECAST REVIEW FOR RNA VACCINES BY GEOGRAPHIC REGION
12.1 Global RNA Vaccines Market Size Forecast by Region
12.1.1 Global RNA Vaccines Forecast by Region (2026-2031)
12.1.2 Global RNA Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global RNA Vaccines Forecast by Type (2026-2031)
12.7 Global RNA Vaccines Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Moderna Therapeutics
13.1.1 Moderna Therapeutics Company Information
13.1.2 Moderna Therapeutics RNA Vaccines Product Portfolios and Specifications
13.1.3 Moderna Therapeutics RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Moderna Therapeutics Main Business Overview
13.1.5 Moderna Therapeutics Latest Developments
13.2 CureVac
13.2.1 CureVac Company Information
13.2.2 CureVac RNA Vaccines Product Portfolios and Specifications
13.2.3 CureVac RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 CureVac Main Business Overview
13.2.5 CureVac Latest Developments
13.3 Translate Bio
13.3.1 Translate Bio Company Information
13.3.2 Translate Bio RNA Vaccines Product Portfolios and Specifications
13.3.3 Translate Bio RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Translate Bio Main Business Overview
13.3.5 Translate Bio Latest Developments
13.4 BioNTech
13.4.1 BioNTech Company Information
13.4.2 BioNTech RNA Vaccines Product Portfolios and Specifications
13.4.3 BioNTech RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 BioNTech Main Business Overview
13.4.5 BioNTech Latest Developments
13.5 Sangamo Therapeutics
13.5.1 Sangamo Therapeutics Company Information
13.5.2 Sangamo Therapeutics RNA Vaccines Product Portfolios and Specifications
13.5.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Sangamo Therapeutics Main Business Overview
13.5.5 Sangamo Therapeutics Latest Developments
13.6 Argos Therapeutics
13.6.1 Argos Therapeutics Company Information
13.6.2 Argos Therapeutics RNA Vaccines Product Portfolios and Specifications
13.6.3 Argos Therapeutics RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Argos Therapeutics Main Business Overview
13.6.5 Argos Therapeutics Latest Developments
13.7 In-Cell-Art
13.7.1 In-Cell-Art Company Information
13.7.2 In-Cell-Art RNA Vaccines Product Portfolios and Specifications
13.7.3 In-Cell-Art RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 In-Cell-Art Main Business Overview
13.7.5 In-Cell-Art Latest Developments
13.8 eTheRNA
13.8.1 eTheRNA Company Information
13.8.2 eTheRNA RNA Vaccines Product Portfolios and Specifications
13.8.3 eTheRNA RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 eTheRNA Main Business Overview
13.8.5 eTheRNA Latest Developments
13.9 Ethris
13.9.1 Ethris Company Information
13.9.2 Ethris RNA Vaccines Product Portfolios and Specifications
13.9.3 Ethris RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Ethris Main Business Overview
13.9.5 Ethris Latest Developments
13.10 Tiba Biotechnology
13.10.1 Tiba Biotechnology Company Information
13.10.2 Tiba Biotechnology RNA Vaccines Product Portfolios and Specifications
13.10.3 Tiba Biotechnology RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Tiba Biotechnology Main Business Overview
13.10.5 Tiba Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Vaccines Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for RNA Vaccines by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for RNA Vaccines by Country/Region, 2020, 2024 & 2031
2.2 RNA Vaccines Segment by Type
2.2.1 Individualized Cancer Treatment MRNA Vaccine
2.2.2 Infectious Disease Treatment MRNA Vaccine
2.2.3 Infection Prevention MRNA Vaccine
2.3 RNA Vaccines Sales by Type
2.3.1 Global RNA Vaccines Sales Market Share by Type (2020-2025)
2.3.2 Global RNA Vaccines Revenue and Market Share by Type (2020-2025)
2.3.3 Global RNA Vaccines Sale Price by Type (2020-2025)
2.4 RNA Vaccines Segment by Application
2.4.1 Infectious Disease
2.4.2 Cancer
2.4.3 Other
2.5 RNA Vaccines Sales by Application
2.5.1 Global RNA Vaccines Sale Market Share by Application (2020-2025)
2.5.2 Global RNA Vaccines Revenue and Market Share by Application (2020-2025)
2.5.3 Global RNA Vaccines Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global RNA Vaccines Breakdown Data by Company
3.1.1 Global RNA Vaccines Annual Sales by Company (2020-2025)
3.1.2 Global RNA Vaccines Sales Market Share by Company (2020-2025)
3.2 Global RNA Vaccines Annual Revenue by Company (2020-2025)
3.2.1 Global RNA Vaccines Revenue by Company (2020-2025)
3.2.2 Global RNA Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global RNA Vaccines Sale Price by Company
3.4 Key Manufacturers RNA Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Vaccines Product Location Distribution
3.4.2 Players RNA Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RNA VACCINES BY GEOGRAPHIC REGION
4.1 World Historic RNA Vaccines Market Size by Geographic Region (2020-2025)
4.1.1 Global RNA Vaccines Annual Sales by Geographic Region (2020-2025)
4.1.2 Global RNA Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic RNA Vaccines Market Size by Country/Region (2020-2025)
4.2.1 Global RNA Vaccines Annual Sales by Country/Region (2020-2025)
4.2.2 Global RNA Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas RNA Vaccines Sales Growth
4.4 APAC RNA Vaccines Sales Growth
4.5 Europe RNA Vaccines Sales Growth
4.6 Middle East & Africa RNA Vaccines Sales Growth
5 AMERICAS
5.1 Americas RNA Vaccines Sales by Country
5.1.1 Americas RNA Vaccines Sales by Country (2020-2025)
5.1.2 Americas RNA Vaccines Revenue by Country (2020-2025)
5.2 Americas RNA Vaccines Sales by Type (2020-2025)
5.3 Americas RNA Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Vaccines Sales by Region
6.1.1 APAC RNA Vaccines Sales by Region (2020-2025)
6.1.2 APAC RNA Vaccines Revenue by Region (2020-2025)
6.2 APAC RNA Vaccines Sales by Type (2020-2025)
6.3 APAC RNA Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe RNA Vaccines by Country
7.1.1 Europe RNA Vaccines Sales by Country (2020-2025)
7.1.2 Europe RNA Vaccines Revenue by Country (2020-2025)
7.2 Europe RNA Vaccines Sales by Type (2020-2025)
7.3 Europe RNA Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Vaccines by Country
8.1.1 Middle East & Africa RNA Vaccines Sales by Country (2020-2025)
8.1.2 Middle East & Africa RNA Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa RNA Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa RNA Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Vaccines
10.3 Manufacturing Process Analysis of RNA Vaccines
10.4 Industry Chain Structure of RNA Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Vaccines Distributors
11.3 RNA Vaccines Customer
12 WORLD FORECAST REVIEW FOR RNA VACCINES BY GEOGRAPHIC REGION
12.1 Global RNA Vaccines Market Size Forecast by Region
12.1.1 Global RNA Vaccines Forecast by Region (2026-2031)
12.1.2 Global RNA Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global RNA Vaccines Forecast by Type (2026-2031)
12.7 Global RNA Vaccines Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Moderna Therapeutics
13.1.1 Moderna Therapeutics Company Information
13.1.2 Moderna Therapeutics RNA Vaccines Product Portfolios and Specifications
13.1.3 Moderna Therapeutics RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Moderna Therapeutics Main Business Overview
13.1.5 Moderna Therapeutics Latest Developments
13.2 CureVac
13.2.1 CureVac Company Information
13.2.2 CureVac RNA Vaccines Product Portfolios and Specifications
13.2.3 CureVac RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 CureVac Main Business Overview
13.2.5 CureVac Latest Developments
13.3 Translate Bio
13.3.1 Translate Bio Company Information
13.3.2 Translate Bio RNA Vaccines Product Portfolios and Specifications
13.3.3 Translate Bio RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Translate Bio Main Business Overview
13.3.5 Translate Bio Latest Developments
13.4 BioNTech
13.4.1 BioNTech Company Information
13.4.2 BioNTech RNA Vaccines Product Portfolios and Specifications
13.4.3 BioNTech RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 BioNTech Main Business Overview
13.4.5 BioNTech Latest Developments
13.5 Sangamo Therapeutics
13.5.1 Sangamo Therapeutics Company Information
13.5.2 Sangamo Therapeutics RNA Vaccines Product Portfolios and Specifications
13.5.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Sangamo Therapeutics Main Business Overview
13.5.5 Sangamo Therapeutics Latest Developments
13.6 Argos Therapeutics
13.6.1 Argos Therapeutics Company Information
13.6.2 Argos Therapeutics RNA Vaccines Product Portfolios and Specifications
13.6.3 Argos Therapeutics RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Argos Therapeutics Main Business Overview
13.6.5 Argos Therapeutics Latest Developments
13.7 In-Cell-Art
13.7.1 In-Cell-Art Company Information
13.7.2 In-Cell-Art RNA Vaccines Product Portfolios and Specifications
13.7.3 In-Cell-Art RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 In-Cell-Art Main Business Overview
13.7.5 In-Cell-Art Latest Developments
13.8 eTheRNA
13.8.1 eTheRNA Company Information
13.8.2 eTheRNA RNA Vaccines Product Portfolios and Specifications
13.8.3 eTheRNA RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 eTheRNA Main Business Overview
13.8.5 eTheRNA Latest Developments
13.9 Ethris
13.9.1 Ethris Company Information
13.9.2 Ethris RNA Vaccines Product Portfolios and Specifications
13.9.3 Ethris RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Ethris Main Business Overview
13.9.5 Ethris Latest Developments
13.10 Tiba Biotechnology
13.10.1 Tiba Biotechnology Company Information
13.10.2 Tiba Biotechnology RNA Vaccines Product Portfolios and Specifications
13.10.3 Tiba Biotechnology RNA Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Tiba Biotechnology Main Business Overview
13.10.5 Tiba Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. RNA Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. RNA Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Individualized Cancer Treatment MRNA Vaccine
Table 4. Major Players of Infectious Disease Treatment MRNA Vaccine
Table 5. Major Players of Infection Prevention MRNA Vaccine
Table 6. Global RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 7. Global RNA Vaccines Sales Market Share by Type (2020-2025)
Table 8. Global RNA Vaccines Revenue by Type (2020-2025) & ($ million)
Table 9. Global RNA Vaccines Revenue Market Share by Type (2020-2025)
Table 10. Global RNA Vaccines Sale Price by Type (2020-2025) & (USD/Dose)
Table 11. Global RNA Vaccines Sale by Application (2020-2025) & (K Doses)
Table 12. Global RNA Vaccines Sale Market Share by Application (2020-2025)
Table 13. Global RNA Vaccines Revenue by Application (2020-2025) & ($ million)
Table 14. Global RNA Vaccines Revenue Market Share by Application (2020-2025)
Table 15. Global RNA Vaccines Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global RNA Vaccines Sales by Company (2020-2025) & (K Doses)
Table 17. Global RNA Vaccines Sales Market Share by Company (2020-2025)
Table 18. Global RNA Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 19. Global RNA Vaccines Revenue Market Share by Company (2020-2025)
Table 20. Global RNA Vaccines Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers RNA Vaccines Producing Area Distribution and Sales Area
Table 22. Players RNA Vaccines Products Offered
Table 23. RNA Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global RNA Vaccines Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global RNA Vaccines Sales Market Share Geographic Region (2020-2025)
Table 28. Global RNA Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global RNA Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global RNA Vaccines Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global RNA Vaccines Sales Market Share by Country/Region (2020-2025)
Table 32. Global RNA Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global RNA Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas RNA Vaccines Sales by Country (2020-2025) & (K Doses)
Table 35. Americas RNA Vaccines Sales Market Share by Country (2020-2025)
Table 36. Americas RNA Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 38. Americas RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 39. APAC RNA Vaccines Sales by Region (2020-2025) & (K Doses)
Table 40. APAC RNA Vaccines Sales Market Share by Region (2020-2025)
Table 41. APAC RNA Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 43. APAC RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 44. Europe RNA Vaccines Sales by Country (2020-2025) & (K Doses)
Table 45. Europe RNA Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 47. Europe RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa RNA Vaccines Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa RNA Vaccines Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 51. Middle East & Africa RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of RNA Vaccines
Table 53. Key Market Challenges & Risks of RNA Vaccines
Table 54. Key Industry Trends of RNA Vaccines
Table 55. RNA Vaccines Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. RNA Vaccines Distributors List
Table 58. RNA Vaccines Customer List
Table 59. Global RNA Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 60. Global RNA Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas RNA Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 62. Americas RNA Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC RNA Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 64. APAC RNA Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe RNA Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 66. Europe RNA Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa RNA Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa RNA Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global RNA Vaccines Sales Forecast by Type (2026-2031) & (K Doses)
Table 70. Global RNA Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global RNA Vaccines Sales Forecast by Application (2026-2031) & (K Doses)
Table 72. Global RNA Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Moderna Therapeutics Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 74. Moderna Therapeutics RNA Vaccines Product Portfolios and Specifications
Table 75. Moderna Therapeutics RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. Moderna Therapeutics Main Business
Table 77. Moderna Therapeutics Latest Developments
Table 78. CureVac Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. CureVac RNA Vaccines Product Portfolios and Specifications
Table 80. CureVac RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. CureVac Main Business
Table 82. CureVac Latest Developments
Table 83. Translate Bio Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Translate Bio RNA Vaccines Product Portfolios and Specifications
Table 85. Translate Bio RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Translate Bio Main Business
Table 87. Translate Bio Latest Developments
Table 88. BioNTech Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. BioNTech RNA Vaccines Product Portfolios and Specifications
Table 90. BioNTech RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. BioNTech Main Business
Table 92. BioNTech Latest Developments
Table 93. Sangamo Therapeutics Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Sangamo Therapeutics RNA Vaccines Product Portfolios and Specifications
Table 95. Sangamo Therapeutics RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Sangamo Therapeutics Main Business
Table 97. Sangamo Therapeutics Latest Developments
Table 98. Argos Therapeutics Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Argos Therapeutics RNA Vaccines Product Portfolios and Specifications
Table 100. Argos Therapeutics RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Argos Therapeutics Main Business
Table 102. Argos Therapeutics Latest Developments
Table 103. In-Cell-Art Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. In-Cell-Art RNA Vaccines Product Portfolios and Specifications
Table 105. In-Cell-Art RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. In-Cell-Art Main Business
Table 107. In-Cell-Art Latest Developments
Table 108. eTheRNA Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. eTheRNA RNA Vaccines Product Portfolios and Specifications
Table 110. eTheRNA RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. eTheRNA Main Business
Table 112. eTheRNA Latest Developments
Table 113. Ethris Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Ethris RNA Vaccines Product Portfolios and Specifications
Table 115. Ethris RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Ethris Main Business
Table 117. Ethris Latest Developments
Table 118. Tiba Biotechnology Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Tiba Biotechnology RNA Vaccines Product Portfolios and Specifications
Table 120. Tiba Biotechnology RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Tiba Biotechnology Main Business
Table 122. Tiba Biotechnology Latest Developments
Table 1. RNA Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. RNA Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Individualized Cancer Treatment MRNA Vaccine
Table 4. Major Players of Infectious Disease Treatment MRNA Vaccine
Table 5. Major Players of Infection Prevention MRNA Vaccine
Table 6. Global RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 7. Global RNA Vaccines Sales Market Share by Type (2020-2025)
Table 8. Global RNA Vaccines Revenue by Type (2020-2025) & ($ million)
Table 9. Global RNA Vaccines Revenue Market Share by Type (2020-2025)
Table 10. Global RNA Vaccines Sale Price by Type (2020-2025) & (USD/Dose)
Table 11. Global RNA Vaccines Sale by Application (2020-2025) & (K Doses)
Table 12. Global RNA Vaccines Sale Market Share by Application (2020-2025)
Table 13. Global RNA Vaccines Revenue by Application (2020-2025) & ($ million)
Table 14. Global RNA Vaccines Revenue Market Share by Application (2020-2025)
Table 15. Global RNA Vaccines Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global RNA Vaccines Sales by Company (2020-2025) & (K Doses)
Table 17. Global RNA Vaccines Sales Market Share by Company (2020-2025)
Table 18. Global RNA Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 19. Global RNA Vaccines Revenue Market Share by Company (2020-2025)
Table 20. Global RNA Vaccines Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers RNA Vaccines Producing Area Distribution and Sales Area
Table 22. Players RNA Vaccines Products Offered
Table 23. RNA Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global RNA Vaccines Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global RNA Vaccines Sales Market Share Geographic Region (2020-2025)
Table 28. Global RNA Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global RNA Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global RNA Vaccines Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global RNA Vaccines Sales Market Share by Country/Region (2020-2025)
Table 32. Global RNA Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global RNA Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas RNA Vaccines Sales by Country (2020-2025) & (K Doses)
Table 35. Americas RNA Vaccines Sales Market Share by Country (2020-2025)
Table 36. Americas RNA Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 38. Americas RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 39. APAC RNA Vaccines Sales by Region (2020-2025) & (K Doses)
Table 40. APAC RNA Vaccines Sales Market Share by Region (2020-2025)
Table 41. APAC RNA Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 43. APAC RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 44. Europe RNA Vaccines Sales by Country (2020-2025) & (K Doses)
Table 45. Europe RNA Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 47. Europe RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa RNA Vaccines Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa RNA Vaccines Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa RNA Vaccines Sales by Type (2020-2025) & (K Doses)
Table 51. Middle East & Africa RNA Vaccines Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of RNA Vaccines
Table 53. Key Market Challenges & Risks of RNA Vaccines
Table 54. Key Industry Trends of RNA Vaccines
Table 55. RNA Vaccines Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. RNA Vaccines Distributors List
Table 58. RNA Vaccines Customer List
Table 59. Global RNA Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 60. Global RNA Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas RNA Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 62. Americas RNA Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC RNA Vaccines Sales Forecast by Region (2026-2031) & (K Doses)
Table 64. APAC RNA Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe RNA Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 66. Europe RNA Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa RNA Vaccines Sales Forecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa RNA Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global RNA Vaccines Sales Forecast by Type (2026-2031) & (K Doses)
Table 70. Global RNA Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global RNA Vaccines Sales Forecast by Application (2026-2031) & (K Doses)
Table 72. Global RNA Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Moderna Therapeutics Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 74. Moderna Therapeutics RNA Vaccines Product Portfolios and Specifications
Table 75. Moderna Therapeutics RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. Moderna Therapeutics Main Business
Table 77. Moderna Therapeutics Latest Developments
Table 78. CureVac Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. CureVac RNA Vaccines Product Portfolios and Specifications
Table 80. CureVac RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. CureVac Main Business
Table 82. CureVac Latest Developments
Table 83. Translate Bio Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Translate Bio RNA Vaccines Product Portfolios and Specifications
Table 85. Translate Bio RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Translate Bio Main Business
Table 87. Translate Bio Latest Developments
Table 88. BioNTech Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. BioNTech RNA Vaccines Product Portfolios and Specifications
Table 90. BioNTech RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. BioNTech Main Business
Table 92. BioNTech Latest Developments
Table 93. Sangamo Therapeutics Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Sangamo Therapeutics RNA Vaccines Product Portfolios and Specifications
Table 95. Sangamo Therapeutics RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Sangamo Therapeutics Main Business
Table 97. Sangamo Therapeutics Latest Developments
Table 98. Argos Therapeutics Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Argos Therapeutics RNA Vaccines Product Portfolios and Specifications
Table 100. Argos Therapeutics RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Argos Therapeutics Main Business
Table 102. Argos Therapeutics Latest Developments
Table 103. In-Cell-Art Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. In-Cell-Art RNA Vaccines Product Portfolios and Specifications
Table 105. In-Cell-Art RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. In-Cell-Art Main Business
Table 107. In-Cell-Art Latest Developments
Table 108. eTheRNA Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. eTheRNA RNA Vaccines Product Portfolios and Specifications
Table 110. eTheRNA RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. eTheRNA Main Business
Table 112. eTheRNA Latest Developments
Table 113. Ethris Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Ethris RNA Vaccines Product Portfolios and Specifications
Table 115. Ethris RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Ethris Main Business
Table 117. Ethris Latest Developments
Table 118. Tiba Biotechnology Basic Information, RNA Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Tiba Biotechnology RNA Vaccines Product Portfolios and Specifications
Table 120. Tiba Biotechnology RNA Vaccines Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Tiba Biotechnology Main Business
Table 122. Tiba Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of RNA Vaccines
Figure 2. RNA Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RNA Vaccines Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global RNA Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. RNA Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. RNA Vaccines Sales Market Share by Country/Region (2024)
Figure 10. RNA Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Individualized Cancer Treatment MRNA Vaccine
Figure 12. Product Picture of Infectious Disease Treatment MRNA Vaccine
Figure 13. Product Picture of Infection Prevention MRNA Vaccine
Figure 14. Global RNA Vaccines Sales Market Share by Type in 2025
Figure 15. Global RNA Vaccines Revenue Market Share by Type (2020-2025)
Figure 16. RNA Vaccines Consumed in Infectious Disease
Figure 17. Global RNA Vaccines Market: Infectious Disease (2020-2025) & (K Doses)
Figure 18. RNA Vaccines Consumed in Cancer
Figure 19. Global RNA Vaccines Market: Cancer (2020-2025) & (K Doses)
Figure 20. RNA Vaccines Consumed in Other
Figure 21. Global RNA Vaccines Market: Other (2020-2025) & (K Doses)
Figure 22. Global RNA Vaccines Sale Market Share by Application (2024)
Figure 23. Global RNA Vaccines Revenue Market Share by Application in 2025
Figure 24. RNA Vaccines Sales by Company in 2025 (K Doses)
Figure 25. Global RNA Vaccines Sales Market Share by Company in 2025
Figure 26. RNA Vaccines Revenue by Company in 2025 ($ millions)
Figure 27. Global RNA Vaccines Revenue Market Share by Company in 2025
Figure 28. Global RNA Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global RNA Vaccines Revenue Market Share by Geographic Region in 2025
Figure 30. Americas RNA Vaccines Sales 2020-2025 (K Doses)
Figure 31. Americas RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 32. APAC RNA Vaccines Sales 2020-2025 (K Doses)
Figure 33. APAC RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 34. Europe RNA Vaccines Sales 2020-2025 (K Doses)
Figure 35. Europe RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa RNA Vaccines Sales 2020-2025 (K Doses)
Figure 37. Middle East & Africa RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 38. Americas RNA Vaccines Sales Market Share by Country in 2025
Figure 39. Americas RNA Vaccines Revenue Market Share by Country (2020-2025)
Figure 40. Americas RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 41. Americas RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 42. United States RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC RNA Vaccines Sales Market Share by Region in 2025
Figure 47. APAC RNA Vaccines Revenue Market Share by Region (2020-2025)
Figure 48. APAC RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 49. APAC RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 50. China RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. India RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe RNA Vaccines Sales Market Share by Country in 2025
Figure 58. Europe RNA Vaccines Revenue Market Share by Country (2020-2025)
Figure 59. Europe RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 60. Europe RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 61. Germany RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 62. France RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. UK RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa RNA Vaccines Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 69. Egypt RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of RNA Vaccines in 2025
Figure 75. Manufacturing Process Analysis of RNA Vaccines
Figure 76. Industry Chain Structure of RNA Vaccines
Figure 77. Channels of Distribution
Figure 78. Global RNA Vaccines Sales Market Forecast by Region (2026-2031)
Figure 79. Global RNA Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global RNA Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global RNA Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global RNA Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global RNA Vaccines Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of RNA Vaccines
Figure 2. RNA Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global RNA Vaccines Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global RNA Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. RNA Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. RNA Vaccines Sales Market Share by Country/Region (2024)
Figure 10. RNA Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Individualized Cancer Treatment MRNA Vaccine
Figure 12. Product Picture of Infectious Disease Treatment MRNA Vaccine
Figure 13. Product Picture of Infection Prevention MRNA Vaccine
Figure 14. Global RNA Vaccines Sales Market Share by Type in 2025
Figure 15. Global RNA Vaccines Revenue Market Share by Type (2020-2025)
Figure 16. RNA Vaccines Consumed in Infectious Disease
Figure 17. Global RNA Vaccines Market: Infectious Disease (2020-2025) & (K Doses)
Figure 18. RNA Vaccines Consumed in Cancer
Figure 19. Global RNA Vaccines Market: Cancer (2020-2025) & (K Doses)
Figure 20. RNA Vaccines Consumed in Other
Figure 21. Global RNA Vaccines Market: Other (2020-2025) & (K Doses)
Figure 22. Global RNA Vaccines Sale Market Share by Application (2024)
Figure 23. Global RNA Vaccines Revenue Market Share by Application in 2025
Figure 24. RNA Vaccines Sales by Company in 2025 (K Doses)
Figure 25. Global RNA Vaccines Sales Market Share by Company in 2025
Figure 26. RNA Vaccines Revenue by Company in 2025 ($ millions)
Figure 27. Global RNA Vaccines Revenue Market Share by Company in 2025
Figure 28. Global RNA Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global RNA Vaccines Revenue Market Share by Geographic Region in 2025
Figure 30. Americas RNA Vaccines Sales 2020-2025 (K Doses)
Figure 31. Americas RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 32. APAC RNA Vaccines Sales 2020-2025 (K Doses)
Figure 33. APAC RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 34. Europe RNA Vaccines Sales 2020-2025 (K Doses)
Figure 35. Europe RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa RNA Vaccines Sales 2020-2025 (K Doses)
Figure 37. Middle East & Africa RNA Vaccines Revenue 2020-2025 ($ millions)
Figure 38. Americas RNA Vaccines Sales Market Share by Country in 2025
Figure 39. Americas RNA Vaccines Revenue Market Share by Country (2020-2025)
Figure 40. Americas RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 41. Americas RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 42. United States RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC RNA Vaccines Sales Market Share by Region in 2025
Figure 47. APAC RNA Vaccines Revenue Market Share by Region (2020-2025)
Figure 48. APAC RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 49. APAC RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 50. China RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. India RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe RNA Vaccines Sales Market Share by Country in 2025
Figure 58. Europe RNA Vaccines Revenue Market Share by Country (2020-2025)
Figure 59. Europe RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 60. Europe RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 61. Germany RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 62. France RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. UK RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa RNA Vaccines Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa RNA Vaccines Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa RNA Vaccines Sales Market Share by Application (2020-2025)
Figure 69. Egypt RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries RNA Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of RNA Vaccines in 2025
Figure 75. Manufacturing Process Analysis of RNA Vaccines
Figure 76. Industry Chain Structure of RNA Vaccines
Figure 77. Channels of Distribution
Figure 78. Global RNA Vaccines Sales Market Forecast by Region (2026-2031)
Figure 79. Global RNA Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global RNA Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global RNA Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global RNA Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global RNA Vaccines Revenue Market Share Forecast by Application (2026-2031)
